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ARTICLE OPEN
Impact of multiple-dose versus single-dose inhaler devices on
COPD patients’ persistence with long-acting β2-agonists:
a dispensing database analysis
Job FM van Boven1, Joost J van Raaij1, Ruben van der Galiën1, Maarten J Postma1, Thys van der Molen2, PN Richard Dekhuijzen3
and Stefan Vegter1
BACKGROUND: With a growing availability of different devices and types of medication, additional evidence is required to assist
clinicians in prescribing the optimal medication in relation to chronic obstructive pulmonary disease (COPD) patients’ persistence
with long-acting β2-agonists (LABAs).
AIMS: To assess the impact of the type of inhaler device (multiple-dose versus single-dose inhalers) on 1-year persistence and
switching patterns with LABAs.
METHODS: A retrospective observational cohort study was performed comparing a cohort of patients initiating multiple-dose
inhalers and a cohort initiating single-dose inhalers. The study population consisted of long-acting bronchodilator naive COPD
patients, initiating inhalation therapy with mono-LABAs (formoterol, indacaterol or salmeterol). Analyses were performed using
pharmacy dispensing data from 1994 to 2012, obtained from the IADB.nl database. Study outcomes were 1-year persistence and
switching patterns. Results were adjusted for initial prescriber, initial medication, dosing regimen and relevant comorbidities.
RESULTS: In all, 575 patients initiating LABAs were included in the ﬁnal study cohort. Among them, 475 (83%) initiated a multiple-
dose inhaler and 100 (17%) a single-dose inhaler. Further, 269 (47%) initiated formoterol, 9 (2%) indacaterol and 297 (52%)
salmeterol. There was no signiﬁcant difference in persistence between users of multiple-dose or single-dose inhalers (hazard ratio:
0.98, 95% conﬁdence interval: 0.76–1.26, P= 0.99). Over 80% re-started or switched medication.
CONCLUSIONS: There seems no impact of inhaler device (multiple-dose versus single-dose inhalers) on COPD patients’ persistence
with LABAs. Over 80% of patients who initially seemed to discontinue LABAs, re-started their initial medication or switched inhalers
or medication within 1 year.
npj Primary Care Respiratory Medicine (2014) 24, 14069; doi:10.1038/npjpcrm.2014.69; published online 2 October 2014
INTRODUCTION
Chronic obstructive pulmonary disease (COPD) places a high
burden on both public health and health-care budgets of patients
and the government.1,2 Despite no curative treatment being
available, inhaled medication has been shown to reduce disease
symptoms.3,4 However, effectiveness of current medication has
mainly been assessed in controlled clinical trial settings, which
may not properly reﬂect real-life behavior of patients. Further-
more, these trial populations do not fully represent the
characteristics of the average COPD population.5 Both factors
contribute to a real-life adherence to COPD medication that is far
beyond adherence reported in clinical trials.6,7 Recently, non-
adherent patients were highlighted as a target for interventions
because of the signiﬁcant clinical and economic impact of non-
adherence on patients with COPD.8 Factors associated with non-
adherence with COPD medication include age, comorbidity,
disease severity and class of medication.9,10 However, only a few
factors may be modiﬁed by the prescribing clinician. Compared to
the abundant number of adherence studies in asthma patients,
studies on patients with COPD are limited.6,7,11–13 In particular,
studies assessing the impact of the type of inhaler device on
medication adherence in patients with COPD are lacking.14 With a
growing availability of different types of medication and inhaler
devices, additional evidence is required to assist clinicians in
prescribing the optimal medication in relation to their patients’
adherence. Adherence does encompass compliance (the extent of
acting according to the prescribers’ advice) and persistence
(duration of time from initiation till discontinuation of therapy).15
The objective of this study is to assess the impact of the type of
inhalation device on COPD patients’ persistence with, and
switching between, long-acting respiratory medication. The focus
on persistence was chosen as this could be objectively measured
using a dispensing database, whereas compliance would require
face-to-face assessment of patients. In particular, we focused on
persistence with long-acting β2-agonists (LABAs), where we
compared single-dose versus multiple-dose inhalers.
MATERIALS AND METHODS
Data source
Data were obtained from the InterActionDatabase (IADB.nl, available from
http://www.iadb.nl). The IADB.nl database covers pharmacy-dispensing
data from over 500,000 patients from 55 community pharmacies located in
the Northern Netherlands between 1994 and 2012. Dispensing data
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contain information on drug name, product speciﬁcations, anatomical
therapeutic chemical code, prescriber, amount of delivered drug units,
daily dose and patient characteristics such as date of birth, gender and
socioeconomic status, regardless of health-care insurance status of the
patients. Thus, the database is representative for the real-world situation in
the Netherlands. Medication dispensed in hospitals is not included. The
IADB.nl database has been validated for drug utilisation studies16 and has
been used in previous persistence studies.17,18 In the Netherlands, patients
usually redeem their prescriptions at the same pharmacy allowing a
complete longitudinal follow-up.
Study population
As the database lacked data on clinical diagnosis, COPD patients were
selected based on initiation of inhaled respiratory medication above the
age of 55 years, in line with previous studies.7,12 Treatment initiation was
deﬁned as at least one prescription of LABAs for inhalation (salmeterol
(R03AC12), formoterol (R03AC13), or indacaterol (R03AC18)). The group of
LABAs was chosen as for this group both dry powder inhalers (DPIs) and
pressurised metered dose inhalers are available. Moreover, within the DPI
group, both single-dose as well as multiple-dose inhalers are available,
making this the group of long-acting bronchodilators where the inﬂuence
of inhaler device could be most extensively tested. Starters were deﬁned as
not having used any long-acting respiratory medications (LABAs, inhaled
corticosteroids (ICS) or long-acting muscarinic antagonists) for at least
2 years before treatment initiation. To make sure that a complete overview
of history and follow-up was available, patients needed to be registered in
the database at least 2 years before and 1 year after initiation of therapy.
We only included patients who started one type of inhaled medication at
treatment initiation (that is, patients who started a LABA and at the same
date ICS or long-acting muscarinic antagonist were excluded). To minimise
the possibility to include (late onset) asthma patients, we excluded
patients using typical asthma medication (antihistamines (R06), anti-
allergics (R03BC), leukotriene receptor antagonists (R03DC), and omaluzi-
mab (R03DX05)) within 1 year after long-acting beta agonist initiation.
Persistence
Continuous drug use in the ﬁrst year was calculated by the total number of
doses dispensed from therapy initiation, divided by the prescribed daily
dose. A gap of maximal 60 days without medication coverage within the
period of continuous use was allowed to consider a patient being still
persistent to medication, that is, patients who did not have any gaps
exceeding 60 days in the 1-year period after therapy initiation was
considered persistent. This 60-day gap is a common cutoff and was used in
various previous studies assessing persistence with COPD medication.6,7
Switching
Part of the nonpersistent patients were those who did discontinue their
initial inhaler or medication but did not completely discontinue the use of
any long-acting medication at all (that is, they switched therapy).
Therefore, follow-up of non-persistent (to initial therapy) patients was
monitored by assessing patients’ medication proﬁles after the date of
discontinuation of their initial therapy. For all patients, follow-up was at
least 1 year from the date of treatment initiation; however, to be able to
assess switching patterns in the year after the date of treatment
discontinuation, follow-up needed to be longer. Therefore, we deﬁned a
subcohort where patients needed to have a follow-up of at least 2 years.
After discontinuation of initial treatment, we assessed the following
possibilities: a switch to a different inhaler within the DPI class (that is, from
single- to multiple-dose inhaler or vice versa), a switch to a LABA-
pressurised metered dose inhaler, a switch to a different bronchodilator
class (LABA/ICS or long-acting muscarinic antagonist), a restart with initial
type of medication/inhaler or permanent discontinuation of any long-
acting bronchodilator.
Deﬁning the single-dose and multiple-dose cohorts
Two cohorts were deﬁned based on the type of LABA-DPI initiated by the
patients. We made a distinction between single-dose and multiple-dose
DPI inhalers. Single-dose inhalers require loading of separate capsules
before using the device.19,20 Examples include the Handihaler, the
Cyclohaler, the Rotahaler and the Breezhaler. Multiple-dose inhalers
contain a ﬁxed amount of doses (usually between 60 and 120) that can
be taken successively until the device runs out of doses. Examples include
the Diskus, the Turbuhaler and the Novolizer. We hypothesised that the
use of single-dose inhalers required more complex and time-consuming
handlings in order to perform proper inhalation and would therefore
decrease treatment persistence.
Covariates
Although this study focused on the medication and inhaler devices,
persistence may be altered by several other parameters. The following
parameters were compared between the two cohorts: age, gender,
socioeconomic status, initial prescriber, comorbidity (described in more
detail below), number of short courses of oral corticosteroids, use of
short-acting bronchodilators, initial medication and dosing regimen. We
performed a multivariate analysis to correct for parameters that
signiﬁcantly differed (Po0.05) between the two cohorts.
Comorbidity. Included comorbidities were selected based on
frequently reported comorbidities from previous studies.21 If
available, proxies from earlier studies were used to identify
comorbidities based on medication use.22–24 Diabetes was
identiﬁed by use of glucose-lowering drugs, that is, drugs with
anatomical therapeutic chemical code ‘A10%’. Dyslipidaemia was
identiﬁed by use of lipid-lowering drugs (C10). Heart failure and
ischaemic heart disease were identiﬁed by prescription of digoxin
or loop diuretics (C01AA05 or C03C) and C01DA, respectively.
Patients not using previously mentioned anatomical therapeutic
chemical codes but using other cardiovascular drugs (C02, C03,
C07, C08 or C09) were classiﬁed as patients suffering from other
cardiovascular disorders. Other diseases included osteoporosis
(M05B), anxiety (N05B and N05C), dementia (N06B), depression
(N06A), rheumatic arthritis (M01 and M02) and hypothyroid
disease (H03). Patients needed to have at least two of these
prescriptions within 1 year after COPD treatment initiation to be
considered a chronic user of these comedications.
Statistics
Parameters of the two cohorts were compared using Fisher’s exact tests or
Mann–Whitney U-tests, where appropriate.
Kaplan–Meier survival analyses were used to visualise patients’
persistence over a 1-year-time period, comparing patients initiating
multiple-dose inhalers and single-dose inhalers. In multivariate Cox
proportional hazard analyses, results were adjusted for parameters that
differed between the two cohorts with a 95% conﬁdence level (Po0.05).
Statistics were performed with IBM SPSS Statistics 22 (IBM Corp., Armonk,
NY, USA).
Handling of missing data
Patients without gender or date of birth information were excluded from
the cohort, just as patients who died in the year after treatment initiation.
In case of missing data on essential parameters such as dosing regimen or
amount of inhalers dispensed, patients were also excluded.
Sensitivity analyses
In order to assess the sensitivity of the gap that was chosen to deﬁne
persistence, we also performed an analysis with a 30- and a 90-day gap.
These analyses will ease generalisability of results by allowing comparison
with previous studies using different deﬁnitions of persistence. Sensitivity
analyses were performed for patients with at least two prescriptions for
long-acting bronchodilators (including LABA-ICS or long-acting muscarinic
antagonist) in the year after treatment initiation, that is, one-time users (for
example, in case of an incident exacerbation) were excluded.
RESULTS
Population selection process
In all, 1,838 potential COPD patients initiated a LABA of interest
(formoterol, indacaterol or salmeterol) between 1996 and 2011.
After exclusion of likely asthma patients (223), 1,615 patients
remained. Of these, 595 patients had no complete information
records on essential parameters to calculate persistence (for
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example, dosing regimen or amount of inhalers) and were
excluded, leaving 1,020 patients. Among them, 207 started two
long-acting inhalers on the same date and were excluded, leaving
813 patients. Of those, 238 (29%) started with a pressurised
metered dose inhaler and 575 (71%) started with a DPI. Of all the
DPI users, 475 (83%) initiated a multiple-dose inhaler and 100
(17%) a single-dose inhaler.
A ﬂow diagram is provided in Figure 1. Patient characteristics,
per cohort, are presented in Table 1. Parameters that signiﬁcantly
differed (Po0.05) were the initial prescriber, comorbidities (lipid-
metabolism disorders and psychosis, in particular), the initial
medication and the dosing regimen.
Analysis of persistence
Overall, 1-year persistence in the basecase scenario (60-day
gap, minimal one prescription) was 14.4%. Persistence between
users of multiple-dose and single-dose inhalers did not
signiﬁcantly differ (hazard ratio: 0.96, 95% conﬁdence interval:
0.76–1.22, P= 0.74). In the multivariate analysis, results did not
change (hazard ratio: 0.98, 95% conﬁdence interval: 0.76–1.26,
P= 0.99).
Sensitivity analyses
Impact of the gap. In sensitivity analyses, overall 1-year
persistence changed when increasing or decreasing the gap
allowed for being considered persistent. Decreasing to a 30-day
gap reduced overall persistence to 9.6%, whereas increasing to a
90-day gap improved overall treatment persistence to 19%.
Excluding one-time users. Including only patients with two
prescriptions or more resulted in a cohort of 375 patients
initiating LABAs. Sixty-six (18%) patients initiated a single-dose
inhaler and three hundred nine (82%) a multiple-dose inhaler.
Overall persistence was 21.9%. There was no signiﬁcant difference
between persistence of users of single-dose or multiple-dose
inhalers (25% vs. 21%, P= 0.24). Persistence with initial medication
over time is graphically shown in Figure 2. Note that in this ﬁgure
patients were marked non-persistent when they did not redeem
their next prescription of their initial inhaler within 60 days after
the theoretical end date of their previous prescription (when used
as prescribed). Take into account that the dosing regimen varied
between one and four times per day. The time point of non-
persistence is the theoretical end date of their last prescription
before their ﬁrst gap.
Allowing switching. In Figure 3, persistence with any long-acting
medication over time is shown for a cohort that included only
Figure 1. Flow diagram of the population selection process. Asthma
patients, excluded based on use of antihistamines, anti-allergics,
leukotriene receptor antagonists or omaluzimab; COPD, chronic
obstructive pulmonary disease; double medication, initiating of two
types of inhaled medication at the same date; DPI, dry powder
inhaler; LABA, long-acting β2-agonist; pMDI, pressurised metered
dose inhaler.
Table 1. Patient characteristics (N= 575)
Multiple-
dose
inhalers
(N= 475)
Single-
dose
inhalers
(N= 100)
Patient characteristics N % N % P-value
Gender
Male 226 47.6 55 55.0 0.19a
Age
Mean (s.d.) 69.3 (8.9) 69.6 (9.2) 0.75b
Initial prescriber
Specialist 56 11.8 27 27.0 o0.05a
Socioeconomic status
Mean (s.d.) 0.6 (1.1) 0.6 (1.1) 0.67b
Comorbidity
Osteoporosis 21 4.4 2 2.0 0.40a
Diabetes mellitus 70 14.7 12 12.0 0.53a
Ischaemic heart disease 36 7.6 10 10.0 0.42a
Heart failure 73 15.4 21 21.0 0.18a
Disorders of lipid metabolism 134 28.2 16 16.0 o0.05a
Other cardiovascular disorders 271 57.1 52 52.0 0.38a
Depression 45 9.5 9 9.0 0.99a
Dementia 1 0.2 2 2.0 0.08a
Anxiety 123 25.9 26 26.0 0.99a
Psychosis 7 1.5 6 6.0 o0.05a
Rheumatic arthritis 76 16.0 13 13.0 0.54a
Thyroid disease 28 5.9 3 3.0 0.33a
Number of comorbidities
Mean 1.9 (1.6) 1.7 (1.5) 0.42b
Short-acting bronchodilators
At least one prescription 94 19.8 23 23.0 0.50a
Short courses oral corticosteroids (yearly)
Mean 0.5 (2.1) 0.4 (0.7) 0.36b
Initial medication
Formoterol 224 47.2 45 45.0 o0.05a
Indacaterol 0 0.0 9 9.0
Salmeterol 251 52.8 46 46.0
Dosing regimen
Mean 2.00 (0.50) 1.89 (0.55) o0.05b
Italic, signiﬁcant (Po0.05).
aTwo-sided Fisher’s exact test.
bMann–Whitney U-test.
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patients with two or more prescriptions and allowing switching,
resulting in an overall persistence of 38.4%.
Switching patterns. Figure 4 shows the switching patterns of non-
persistent patients after their ﬁrst 60-days gap. Note that the
switching analysis was performed in a subcohort (N= 307) with at
least two dispensings for long-acting bronchodilators (that is, one-
time users are not included) and a follow-up of at least 2 years
from treatment initiation. In this cohort, 38 out of 53 single-dose
inhaler users were non-persistent and 203 out of 254 multiple-
dose inhaler users. From Figure 4 it is shown that ~ 40% of all
patients (disregarding their inhaler type) re-started their initial
therapy within 1 year after their ﬁrst gap. Less than 19% of the
patients with a gap did permanently discontinue any type of long-
acting respiratory therapy. A considerable percentage of patients
switched to ﬁxed dose inhalers of LABA and ICS. Of the single-
dose inhaler users, 11% switched to multiple-dose inhalers of the
same medication, whereas none of the multiple-dose inhaler users
switched to single-dose inhalers with the same medication.
DISCUSSION
Main ﬁndings
This study showed no signiﬁcant impact of inhaler device on
COPD patients’ persistence with LABAs: persistence of patients
initiating multiple-dose inhalers was comparable to patients
initiating single-dose inhalers. Whereas overall persistence with
LABAs seemed relatively low at ﬁrst sight, this study showed that
~ 40% of all patients (disregarding their inhaler type) re-started
their initial therapy within 1 year. Only 15% of the patients who
seemed to discontinue based on a 60-day treatment gap did
indeed permanently discontinue any type of long-acting
respiratory therapy. A considerable percentage of patients (about
one-third) switched to ﬁxed dose inhalers of LABA and ICS. Of the
single-dose inhaler users, 11% switched to multiple-dose inhalers
of the same medication, whereas none of the multiple-dose
inhaler users switched to single-dose inhalers with the same
medication.
Interpretation of ﬁndings in relation to previously published work
This study is the ﬁrst describing the relationship between inhaler
devices and persistence with COPD maintenance medication. In
asthma, DPI devices have been linked to improved adherence
compared with pressurised metered dose inhalers.25 Speciﬁc
studies in COPD patients assessing the impact of inhaler device on
adherence or persistence are lacking.14 In general, medication
persistence in our study was far short of optimal, for both
multiple-dose as well as single-dose inhalers. This relatively low
persistence is in line with ﬁndings from previous studies;6,7
however, this study showed that over 80% of patients who initially
seemed to discontinue LABAs, based on a 60-day treatment gap,
re-started their initial medication or switched to different types of
inhaler or medication within 1 year after discontinuation. The high
percentage of switching may suggest that for some prescribers it
takes some time to ﬁnd the optimal inhaler and medication to suit
their patients’ preferences regarding persistent use. However,
whereas an optimal inhaler may favour patients’ persistence,
improved disease control and better clinical outcomes are not
guaranteed. Even though in controlled clinical trial settings
comparing inhaler devices no differences in outcomes were
observed,26 in daily practice, many problems with inhalers have
been described.19,20,27 Main problems are related to poor
inhalation technique,28 resulting in suboptimal deposition in the
lungs, oropharyngeal side effects29 and ultimately poor disease
control.30 Instruction on inhalation techniques has been shown to
not only improve adherence but was also associated with better
health-related quality of life.31 Apart from inhalation technique
and lung deposition issues, one can argue whether improved
health outcomes are solely achieved by adherence to respiratory
medication or that COPD patients’ (self-management) skills and
behaviour determine an important part of improved outcomes.
Notably, good adherers with COPD placebo inhalers showed
comparable outcomes on mortality and hospitalisation rates as
good adherers to real medications.32 Vestbo et al.32 describe this
phenomenon as the ‘healthy adherer effect’. It is suggested that
COPD patients who are good adherers to their medication have a
healthier lifestyle in general (similar to more awareness of the
importance of smoking cessation, a healthy diet and intensity of
Figure 2. Persistence with initial inhaled beta agonists of patients
(N= 375) with minimal two dispenses for bronchodilators, allowing a
maximum gap of 60 days: multiple-dose versus single-dose inhalers.
Figure 3. Overall persistence with any long-acting inhaled
medication of patients (N= 375) with minimal two dispenses for
bronchodilators, allowing a maximum gap of 60 days and allowing
switching.
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exercise). In other words, medication non-adherence may be an
indicator of patients’ shortage of disease- and self-management
skills. This reveals an important opportunity for the health-care
provider: actively search for non-adherent COPD patients (for
example, by medication dispense records) and target your
interventions to these patients. Using this strategy, not only
health-care providers’ time is more efﬁciently spent but also the
cost effectiveness of disease management interventions is
expected to increase as non-adherence has a marked effect on
worsened economic outcomes.8
Strengths and limitations
By using real-world and up-to-date data, the results of this study
are expected to be representative for the current situation in the
community. However, whereas relative results are expected to be
generalisable between countries, absolute results may be less
generalisable because of intensive monitoring and lung revalida-
tion programmes currently running in the Netherlands, which may
encourage more adherent behaviour. Some late onset asthma
patients may be incorrectly classiﬁed as COPD patients as the
database does not provide a diagnosis. In addition, some severe
exacerbations (requiring hospital admission) may have been
missed as the database only collects data from community
pharmacies. Although we tried to use the dispensing of short
courses of oral corticosteroids as a proxy for disease severity,
ﬁndings could still be confounded by COPD severity, as neither
lung function data nor a full set of proxies for COPD severity were
available. The last two limitations are related to the size of the
sample. It might be possible that the observed non-difference in
persistence between the two inhaler types resulted from an
insufﬁcient power to detect the persistence difference. Another
possibility is that the persistence difference might only exist, for
example, in those COPD patients using their inhaler four times
per day, and only a small proportion of the studied subjects used
the inhaler at this high frequency.
Implications for future research, policy and practice
In order to optimise patients’ persistence with COPD medication,
we recommend a choice of inhaler depending on patients’
individual abilities to handle the inhaler.33 Besides, factors
relating to optimal prescription, taking into account patients’
preferences34 and interventions on behaviour modiﬁcation (for
example, stimulation of self-management and inhalation techni-
ques), are equally important and may add to patients’ capacity of
acting in a more adherent behaviour.35 In addition, enhancing
health-care providers’ education and communication skills may be
beneﬁcial.36 Targeting these interventions on non-adherent
patients is expected to improve cost effectiveness.8,37
Conclusions
The choice of an appropriate inhaler device is an important issue
regarding COPD patients’ persistence; however, regarding the
inhaler being a multi-dose or a single-dose device does not seem
to affect patients’ persistence with LABAs. Over 80% of patients,
who initially seemed to discontinue LABAs, re-started their initial
medication or switched to a different type of inhaler or medication
within 1 year.
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